These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 18506010

  • 1. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP, Buskens E, Koffijberg H, Algra A.
    Circulation; 2008 Jun 03; 117(22):2875-83. PubMed ID: 18506010
    [Abstract] [Full Text] [Related]

  • 2. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
    Pignone M, Earnshaw S, Pletcher MJ, Tice JA.
    Arch Intern Med; 2007 Feb 12; 167(3):290-5. PubMed ID: 17296886
    [Abstract] [Full Text] [Related]

  • 3. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P, Stenestrand U, Malmberg K, Jönsson B.
    Clin Ther; 2005 Jan 12; 27(1):100-10. PubMed ID: 15763611
    [Abstract] [Full Text] [Related]

  • 4. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF, Heeg BM, Herlitz J, van Hout BA.
    Appl Health Econ Health Policy; 2010 Jan 12; 8(4):251-65. PubMed ID: 20578780
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
    Saini SD, Schoenfeld P, Fendrick AM, Scheiman J.
    Arch Intern Med; 2008 Aug 11; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
    [Abstract] [Full Text] [Related]

  • 6. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
    Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L.
    Int J Technol Assess Health Care; 2007 Aug 11; 23(1):71-9. PubMed ID: 17234019
    [Abstract] [Full Text] [Related]

  • 7. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ, Prevention of Renal and Vascular End Stage Disease Study Group.
    Clin Ther; 2010 Jun 11; 32(6):1103-21. PubMed ID: 20637965
    [Abstract] [Full Text] [Related]

  • 8. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD, Weiss JP, Owens DK.
    Am J Med; 2004 Jun 15; 116(12):797-806. PubMed ID: 15178495
    [Abstract] [Full Text] [Related]

  • 9. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
    Lamotte M, Piñol C, Brotons C, Annemans L, Guardiola E, Evers T, Kubin M.
    Rev Esp Cardiol; 2006 Aug 15; 59(8):807-15. PubMed ID: 16938230
    [Abstract] [Full Text] [Related]

  • 10. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM, Szucs TD.
    Ital Heart J; 2001 Mar 15; 2(3):181-8. PubMed ID: 11305529
    [Abstract] [Full Text] [Related]

  • 11. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
    Annemans L, Lamotte M, Kubin M, Evers T, Verheugt FW.
    Int J Clin Pract; 2006 Sep 15; 60(9):1129-37. PubMed ID: 16939558
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009 Sep 15; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 13. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T, Fukui T, Lee TH, Matsui K.
    Am J Med; 2004 Oct 01; 117(7):459-68. PubMed ID: 15464702
    [Abstract] [Full Text] [Related]

  • 14. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP, Visseren FL, de Wit GA, Algra A.
    BMJ; 2011 Mar 30; 342():d1672. PubMed ID: 21450800
    [Abstract] [Full Text] [Related]

  • 15. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M.
    Eur Heart J; 2001 Jun 30; 22(11):919-25. PubMed ID: 11428815
    [Abstract] [Full Text] [Related]

  • 16. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals.
    Hur C, Simon LS, Gazelle GS.
    Cancer; 2004 Jul 01; 101(1):189-97. PubMed ID: 15222006
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J, Asselbergs FW, Boersma C, de Vries R, Hillege HL, van Gilst WH, Gansevoort RT, de Jong PE, de Jong-van den Berg LT, Postma MJ, PREVEND IT Study Group.
    Clin Ther; 2006 Mar 01; 28(3):432-44. PubMed ID: 16750458
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of preventive treatment of intracranial aneurysms: new data and uncertainties.
    Greving JP, Rinkel GJ, Buskens E, Algra A.
    Neurology; 2009 Jul 28; 73(4):258-65. PubMed ID: 19299311
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
    Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF.
    Clin Ther; 2012 Jun 28; 34(6):1387-94. PubMed ID: 22560621
    [Abstract] [Full Text] [Related]

  • 20. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
    Martikainen JA, Ottelin AM, Kiviniemi V, Gylling H.
    Eur J Cardiovasc Prev Rehabil; 2007 Apr 28; 14(2):265-72. PubMed ID: 17446806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.